Compare AU

Compare JREG vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Jpmorgan Gl Res En In Eq Active ETF (Managed Fund)

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Jpmorgan Gl Res En In Eq Active ETF (Managed Fund) (JREG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

JREG

CURE

Popularity

Low

Low

Pearlers invested

2

80

Median incremental investment

$4,496.75

$620.00

Median investment frequency

Fortnightly

Monthly

Median total investment

$6,335.81

$1,296.91

Average age group

> 35

> 35


Key Summary

JREG

CURE

Strategy

JREG.AX was created on 2015-05-05 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. To achieve a long-term return in excess of the benchmark,

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

NVIDIA Corp (5.04 %)

Apple Inc (4.82 %)

Microsoft Corp (4.52 %)

Moderna Inc (2.59 %)

Neurocrine Biosciences Inc (2.50 %)

AbbVie Inc (2.40 %)

Top 3 industries

Information Technology (52.77 %)

Other (15.69 %)

Consumer Discretionary (15.54 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (73.29 %)

Japan (4.97 %)

United Kingdom of Great Britain and Northern Ireland (4.05 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.3 %

0.45 %


Key Summary

JREG

CURE

Issuer

JPMorgan

Global X

Tracking index

MSCI World ex Australia Index - AUD - Benchmark TR Net

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.3 %

0.45 %

Price

$77.74

$48.94

Size

N/A

$36.961 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

0.67 %

4.24 %

Market

ASX

ASX

First listed date

09/11/2022

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

JREG

CURE

Popularity

Low

Low

Pearlers invested

2

80

Median incremental investment

$4,496.75

$620.00

Median investment frequency

Fortnightly

Monthly

Median total investment

$6,335.81

$1,296.91

Average age group

> 35

> 35


Pros and Cons

JREG

CURE

Pros

  • Lower management fee

  • Higher price growth

  • Higher exposure to US market

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower distribution yield

  • Higher management fee

  • Lower price growth

JREG

CURE

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home